Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 817 results for "novartis ag"

Data at AAN showed Gilenya(R) high efficacy in achieving 'no e...

Novartis International AG / Data at AAN showed Gilenya® high efficacy in achieving 'no evidence of disease activity' in previously-treated highly-active MS patients . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is ... Reuters, 5 minutes ago
[x]  

58 images for novartis ag

Bloomberg, 3 weeks ago
Channel NewsAsia, 4 weeks ago
FinanzNachrichten.de, 1 month ago
ClinicSpace, 2 months ago
ClinicSpace, 2 months ago
ClinicSpace, 2 months ago
ClinicSpace, 2 months ago
Social Dashboard, 1 month ago
Channel NewsAsia, 1 month ago
BioSpace, 2 months ago
Reuters

Novartis, a leader in targeted therapies, looking to prime the immune system to battle cancer

CAMBRIDGE -- Switzerland's Novartis AG, one of the world's leading cancer drug companies, is making a big bet on emerging science that uses the body's immune system to fight off tumors. Novartis already has 22 oncology drugs on the market treating ...
 Boston Globe7 hours ago FDA Approves Generic MS Drug by Novartis and Momenta  Wall Street Journal UK4 days ago FDA OKs Novartis and Momenta's Generic MS Drug  Austin American Statesman4 days ago FDA Approves Novartis and Momenta's Generic Multiple-Sclerosis Drug  4 Traders4 days ago
[x]  
Reuters

Novartis solid tumor 'CAR T cell' still holds promise - researcher

April 20 (Reuters) - A new type of immuno-oncology treatment from Novartis AG proved safe in a tiny study of three types of solid tumors, but the trial included too few patients and used too small a dose of the experimental product to prove ...
 Reuters UK7 hours ago Novartis solid tumor CAR T cell still holds promise: researcher  The Malaysian Times2 hours ago
[x]  

Novartis AG (NVS) Trading Near $101.44 Support Level

After closing Friday at $102.46, Novartis AG (http://www.marketintelligencecenter.com/symbol/NVS"NVS) presents an attractive opportunity to get a 2.50% return in just 88 days, which is an annualized return of 10.37% (for comparison purposes only).
 Individual.com15 hours ago Novartis AG (NVS) Trading Near $102.22 Support Level  Individual.com4 days ago Novartis AG (NVS) Showing Resistance Near $103.90  Individual.com5 days ago Novartis AG (NVS) Showing Support Near $102.35  Individual.com3 days ago

Novartis 1Q 2015 -- Forecast

FRANKFURT--The following is a summary of analysts' forecasts for Novartis AG (NVS) first-quarter results, based on a poll of 11 analysts conducted by Dow Jones Newswires (figures in million dollars, EPS in dollar and target price in Swiss francs, ...
 4 Traders16 hours ago
[x]  

Unlocking the promise of innovation

Updated: 2015-04-17 10:04 By ED ZHANG(China Daily) Joseph Jimenez, chief executive officer of Novartis AG. [Photo/China Daily] Novartis expects China to play key role in its global development plans and drug research program For ...
 CHINAdaily4 days ago
TheStreet.com

Teva Pharmaceutical Industries (TEVA) Falls On FDA Approval For Novartis AG (ADR) Copaxone Generic

Teva Pharmaceutical Industries Ltd. ( NYSE:TEVA ) stock fell more than 3% during Thursday's trading after the US Food and Drug Administration (FDA) granted approval to the first ever generic drug version of the company's top-selling multiple ...
 Bidness Etc3 days ago Teva Pharmaceuticals (TEVA) Stock Declines Today on Generic Copaxone Approval  TheStreet.com10 hours ago Former Teva CEO Levin to Lead Startup Focused on Brain Diseases  Washington Post4 days ago Teva, Actavis, Other Giants Set to Battle for Generics Space  TheStreet.com5 days ago

Novartis and Momenta Get FDA Nod For Generic Copaxone - Analyst Blog

Novartis AG NVS announced that its generic arm, Sandoz has received FDA approval for Glatopa, the first generic version of Teva Pharmaceuticals TEVA multiple sclerosis (MS) drug, Copaxone 20mg (one time daily). Glatopa, the first substitutable ...
 Yahoo! Finance3 days ago

Maverick Capital Increases Stake in Novartis

Maverick Capital Ups Stakes in Five Companies in 4Q14 (Part 5 of 6) ( Continued from Part 4 ) Maverick Capital and Novartis Maverick Capital increased its position in Novartis (NVS) by more than $22 million in stock. It represented 0.75% of the ...
 Yahoo! Finance3 days ago

Unlocking the promise of innovation

Novartis expects China to play key role in its global development plans and drug research program For Joseph Jimenez, chief executive officer of Novartis AG, making a visit to China is an opportunity to seek ways to participate in the country's ...
 CHINAdaily4 days ago NOVARTIS : Unlocking the promise of innovation  4 Traders4 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - novartis ag
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less